Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

With its hemophilia A gene therapy poised to go through a pivotal program by the end of next year, BioMarin $BMRN is raising hopes for its success with a new batch of Phase I/II data for its valrox program (valoctocogene roxaparvovec/BMN 270).